A recent study indicates that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who end traditional lifestyle plans.
Published data in a prominent health publication points out that while obese individuals frequently drop a large proportion of their body weight while on the medication, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation.
"People purchasing these medications must be cognizant of the risk of rapid weight regain when the therapy is stopped," stated researcher Dr. Susan Jebb.
This pace of regain implies a reversion to starting weight within about 18 months.
Analyzing Therapies
The research, which examined dozens of studies involving thousands of participants, contrasted the outcomes of the injectable medications with other pills.
Scientists note that individuals who shed pounds through diet and exercise usually experience a more gradual creep back—perhaps 100 grams monthly—after stopping.
Explaining the Quick Rebound
Nutrition scientists propose the way of the jabs explains the accelerated rebound.
GLP-1 drugs imitate a natural hormone called GLP-1, which controls appetite.
"Long-term administration of GLP-1 levels far above than the body's typical production could lead to the system to produce less of its endogenous hormone, and could reduce sensitivity to its actions," explained Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication results in appetite is unsuppressed, making binge eating a significant risk."
A Lifelong Disease?
Medical guidelines advise the injections for people with weight-linked health risks, alongside prescribed diet and exercise modifications.
Many experts argue that, given the likelihood of relapse, the treatment is often ongoing.
This opinion is supported by pharmaceutical companies, who note that the results "underscore the chronic nature of excess weight," akin to managing diseases like hypertension.
Patient Testimonies
Users who have come off the jabs report a intense return of cravings.
"I experienced a switch activating and you become ravenous," said one woman.
This difficulty is worsened if patients have not established permanent dietary or behavioural modifications during therapy.
Widespread Adoption
Recent estimates show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is higher among women compared to males.
- The 40s and 50s demographic shows the highest usage rates.
- Many access the drugs through private prescriptions rather than public health services.
In conclusion, researchers stress that while these medications are powerful agents for weight loss, they are not a permanent fix and long-term success likely depends on combined behavioural support.
